In treating hematologic malignancies, engineered T-cell therapy outperforms standard transplantation with respect to chronic ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Cellogen Therapeutics’ CAR T cell technology introduces a bi-specific approach to cancer immunotherapy. Unlike conventional ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

The researchers attribute this to the drugs activating tumor-specific T lymphocytes, a type of immune T cell that ...

Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...

This therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and ...

Using bacteria to fight cancer dates back to the 1860s when William B Coley, often called the father of immunotherapy, ...

The genetic modification of the Natural Killer (NK) cells, lymphocytes forming part of the body’s immune system, would make it possible to retain their capacity of eliminating tumour cells in solid ...

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...